|
Notice under section 708A
|
29 June 2023 at 3:55pm
|
|
Application for quotation of securities - CHM
|
29 June 2023 at 3:50pm
|
|
Results of Extraordinary General Meeting
|
29 June 2023 at 12:10pm
|
|
Application for quotation of securities - CHM
|
23 June 2023 at 3:15pm
|
|
Proposed issue of securities - CHM
|
23 June 2023 at 3:15pm
|
|
Proposed issue of securities - CHM
|
23 June 2023 at 3:05pm
|
|
CHM secures up to A$12.6m through SPP and placements
|
23 June 2023 at 3:05pm
|
|
Application for quotation of securities - CHM
|
23 June 2023 at 12:15pm
|
|
Share purchase plan completed
|
23 June 2023 at 12:15pm
|
|
Chimeric's Phase 1B glioblastoma trial presented at ASCO23
|
6 June 2023 at 11:30am
|
|
Launch of new Phase 1B Glioblastoma clinical trial
|
5 June 2023 at 9:20am
|
|
Update - Proposed issue of securities - CHM
|
2 June 2023 at 8:55am
|
|
Share purchase plan (SPP) - closing date extended
|
2 June 2023 at 8:50am
|
|
Notice of Extraordinary General Meeting/Proxy Form
|
31 May 2023 at 8:45am
|
|
SPP offer documents issued to shareholders
|
23 May 2023 at 9:05am
|
|
SPP Cleansing Notice
|
23 May 2023 at 8:50am
|
|
Proposed issue of securities - CHM
|
15 May 2023 at 10:30am
|
|
Proposed issue of securities - CHM
|
15 May 2023 at 10:15am
|
|
BOARD & MANAGEMENT COMMIT TO $1M PLACEMENT AND PROPOSED SPP
|
15 May 2023 at 10:05am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 April 2023 at 5:35pm
|
|
New CLTX CAR technology patent protection in India & Israel
|
28 April 2023 at 10:10am
|
|
Phase 1B brain cancer clinical trial approved for initiation
|
26 April 2023 at 9:15am
|
|
CHM to host CAR T Cell Therapies Educational Webinar
|
11 April 2023 at 10:30am
|
|
CHM 1101 GBM Abstract Accepted for ASCO 2023 Presentation
|
3 April 2023 at 2:45pm
|
|
Positive pre-IND meeting with FDA for Phase 1 CAR T study
|
21 March 2023 at 10:20am
|
|
Chimeric to present at virtual healthcare conference
|
15 March 2023 at 10:05am
|
|
Completion of Viral Vector Manufacturing for Phase 1 trial
|
9 March 2023 at 8:40am
|
|
Fourth dose cohort initiated in CHM 1101 Phase 1 trial
|
2 March 2023 at 12:55pm
|
|
Appendix 4D and Half Year Report
|
28 February 2023 at 5:35pm
|
|
CHIMERIC RECEIVES $3.06M R&D TAX INCENTIVE
|
14 February 2023 at 3:25pm
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 January 2023 at 3:55pm
|
|
Follow up period completed for 3rd cohort in CHM 1101 trial
|
23 January 2023 at 9:10am
|
|
1st patient dosed in CHM 0201 Vactosertib trial
|
19 January 2023 at 8:55am
|
|
Application for quotation of securities - CHM
|
18 January 2023 at 3:59pm
|
|
Release of Securities from Escrow
|
10 January 2023 at 4:10pm
|
|
Notice under section 708A
|
22 December 2022 at 2:30pm
|
|
Application for quotation of securities - CHM
|
22 December 2022 at 2:25pm
|
|
Dosing complete in 3rd cohort of CHM 1101 (CLTX CAR T) trial
|
22 December 2022 at 10:10am
|
|
Change of Director's Interest Notice - JC
|
15 December 2022 at 5:05pm
|
|
Application for quotation of securities - CHM
|
13 December 2022 at 4:20pm
|
|
Change of Director's Interest Notice - JC
|
24 November 2022 at 11:35am
|
|
License agreement with CWRU - supplementary announcement
|
24 November 2022 at 10:10am
|
|
Exclusive license agreement with CWRU for CORE-NK platform
|
21 November 2022 at 10:40am
|
|
Notification regarding unquoted securities - CHM
|
18 November 2022 at 4:50pm
|
|
Notice under section 708A
|
18 November 2022 at 4:35pm
|
|
Application for quotation of securities - CHM
|
18 November 2022 at 3:40pm
|
|
Results of Meeting
|
15 November 2022 at 2:50pm
|
|
AGM Presentation
|
15 November 2022 at 10:20am
|
|
AGM ATTENDANCE
|
8 November 2022 at 12:20pm
|
|
Sponsored Research Agreement to advance CORE-NK portfolio
|
2 November 2022 at 9:55am
|
Chimeric Therapeutics Ltd